Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amyris Inc    AMRS

Delayed Quote. Delayed  - 10/21 10:00:00 pm
1.11 USD   +3.74%
10/20 AMYRIS INC (NAS : AMRS) Files An 8-K
10/19 2,300,000 SHARE : Amyris Inc. Major Shareholder
10/13 AMYRIS INC (NAS : AMRS) Files An 8-K
News SummaryMost relevantAll newsSector news 

AMYRIS : Cosan and Amyris Forming Novvi S.A. for Global Production and Commercialization of Renewable Base Oils

share with twitter share with LinkedIn share with facebook
share via e-mail
06/13/2011 | 02:15pm CEST

Cosan S.A. Industria e Comércio (BM&FBovespa:CSAN3) and Amyris, Inc. (NASDAQ:AMRS) announced today that they have executed a Joint Venture Implementation Agreement as the final step toward the commencement of operations in Novvi S.A., the Brazilian company established for the worldwide development, production and commercialization of renewable base oils made from Biofene®, Amyris's renewable farnesene. The companies executed in December 2010 an agreement to set the preliminary terms and the general conditions to conduct a set of business, technical and commercial studies and tests with the goal to assess the feasibility of the formation and implementation of a Joint Venture. The parties have now completed feasibility studies and are establishing the operating joint venture entity.

Novvi plans to commercialize a line of synthetic, renewable base oils for the lubricants market. Novvi's base oils are designed to improve upon key environmental metrics including biodegradability, toxicity and renewability when compared with petroleum-sourced base oils, while delivering performance characteristics comparable to Group III and Group IV base oils. Novvi expects to source Biofene initially from Amyris production facilities, convert it through chemical processing into high-end renewable base oils and market and distribute these base oils worldwide. Longer term, Novvi may construct dedicated Biofene production facilities.

"The formation of Novvi provides another important channel for commercialization of Biofene, and we are pleased to have Cosan as our partner in this," said Paulo Diniz, chief executive officer of Amyris Brasil. "We expect Novvi to introduce its first products starting next year."

"We have completed the market studies and production capabilities assessment and are now ready to operate our joint venture with Amyris," said Nelson Gomes, head of Cosan Lubricants. "The combination of Amyris's Biofene infrastructure and technology platform with our feedstock capabilities and supply and distribution infrastructure creates the foundation for Novvi to become the leader in high-performance renewable synthetic base oils."

About Amyris

Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of hydrocarbon molecules - flexible building blocks which can be used in a wide range of products. Amyris is commercializing these products both as No Compromise® renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel. Amyris Brasil S.A., a wholly owned subsidiary, has over 100 employees based in Campinas, Brazil and oversees Amyris's production and commercialization in Brazil. Amyris also has fuel distribution capabilities in the United States through its subsidiary, Amyris Fuels, LLC. More information about Amyris is available at www.amyris.com.

About Cosan

Cosan is a fully integrated energy company. Raízen, its joint venture with Shell, is the world's largest producer of sugar and ethanol from sugarcane, with crushing capacity of 65 million tons of sugarcane, and the third largest fuel distributor in Brazil. Cosan is also the third largest Brazilian lubricants manufacturer and is present in the sugar logistics for the retail market with the União brand and for exports through its subsidiary Rumo.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as statements regarding production, commercialization and anticipated benefits of our products) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production or commercialization of products, our reliance on third parties to achieve our goals, and other risks detailed in the "Risk Factors" section of Amyris's annual report on Form 10-K filed on March 14, 2011 and on Form 10-Q filed May 11, 2011. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris and Biofene are trademarks or registered trademarks of Amyris, Inc.

Amyris, Inc.
Schwartz Communications
Merrill Freund or Alison Mickey, 415-817-2557
Máquina Public Relations, 11 3147-7391
11 3147-7439

© Business Wire 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMYRIS INC
10/20 AMYRIS INC (NASDAQ : AMRS) Files An 8-K
10/19 AMYRIS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct ..
10/19 2,300,000 SHARES OF STOCK ARE SOLD B : Amyris Inc. Major Shareholder
10/13 AMYRIS INC (NASDAQ : AMRS) Files An 8-K
10/13 Amyris Agrees to Collaboration Terms with Leading Global Food Ingredients and..
10/12 AMYRIS, INC. : Entry into a Material Definitive Agreement (form 8-K)
10/06 AMYRIS, INC. : Entry into a Material Definitive Agreement (form 8-K)
10/04 Amyris and Autodesk Offer Powerful Open Source Tools for Genetic Design to En..
10/01 AMYRIS : Expands in Global Nutraceuticals Market with New Collaboration and Part..
09/30 AMYRIS : AMRS) Strengthens Stance in Global Nutraceuticals Market with Collabora..
More news
Sector news : Industrial Biotechnology Chemicals
10/21 After Samarco delay, BHP's 'Jac the knife' to step down
09/29 New Adidas CEO sets off in pursuit of Nike
09/29DJNew Adidas CEO Confronts 'High Bar'
09/19DJUnilever Buys 'Green' Products Maker Seventh Generation
09/07DJEuropean Firms Borrow at Subzero Rates -- WSJ
More sector news : Industrial Biotechnology Chemicals
News from SeekingAlpha
10/19 INSIDERINSIGHTS.COM DAILY ROUND UP 1 : Azz, umh, fbms, opk
10/14 An Update On Amyris - A Juggernaut In The Making
08/16 Amyris - A Juggernaut In The Making
08/04 Amyris' (AMRS) CEO John Melo on Q2 2016 Results - Earnings Call Transcript
08/04 Amyris, Inc. 2016 Q2 - Results - Earnings Call Slides
Financials ($)
Sales 2016 92,6 M
EBIT 2016 -41,0 M
Net income 2016 -54,8 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 2,82x
Capi. / Sales 2017 1,98x
Capitalization 261 M
More Financials
Duration : Period :
Amyris Inc Technical Analysis Chart | AMRS | US03236M1018 | 4-Traders
Full-screen chart
Technical analysis trends AMYRIS INC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 2,68 $
Spread / Average Target 142%
Consensus details
EPS Revisions
More Estimates Revisions
John G. Melo President, Chief Executive Officer & Director
Geoffrey M. Duyk Chairman
Raffi Asadorian Chief Financial Officer
Joel Cherry President-Research & Development
Louis John Doerr Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMYRIS INC-31.48%261
HENKEL AG & CO KGAA15.31%51 832
SIKA AG26.11%10 100
SYMRISE AG2.25%8 860
More Results